Background/Aims To investigate whether non-alcoholic fatty liver disease (NAFLD) in individuals without generalized obesity is associated with visceral fat obesity (VFO), sarcopenia, and/or myosteatosis.
Methods This cross-sectional analysis included 14,400 individuals (7,470 men) who underwent abdominal computed tomography scans during routine health examinations. The total abdominal muscle area (TAMA) and skeletal muscle area (SMA) at the 3rd lumbar vertebral level were measured. The SMA was divided into the normal attenuation muscle area (NAMA) and low attenuation muscle area, and the NAMA/TAMA index was calculated. VFO was defined by visceral to subcutaneous fat ratio, sarcopenia by body mass index-adjusted SMA, and myosteatosis by the NAMA/TAMA index. NAFLD was diagnosed with ultrasonography.
Results Of the 14,400 individuals, 4,748 (33.0%) had NAFLD, and the prevalence of NAFLD among non-obese individuals was 21.4%. In regression analysis, both sarcopenia (men: odds ratio [OR] 1.41, 95% confidence interval [CI] 1.19–1.67, P<0.001; women: OR=1.59, 95% CI 1.40–1.90, P<0.001) and myosteatosis (men: OR=1.24, 95% CI 1.02–1.50, P=0,028; women: OR=1.23, 95% CI 1.04–1.46, P=0.017) were significantly associated with non-obese NAFLD after considering for VFO and other various risk factors, whereas VFO (men: OR=3.97, 95% CI 3.43–4.59 [adjusted for sarcopenia], OR 3.98, 95% CI 3.44–4.60 [adjusted for myosteatosis]; women: OR=5.42, 95% CI 4.53–6.42 [adjusted for sarcopenia], OR=5.33, 95% CI 4.51–6.31 [adjusted for myosteatosis]; all P<0.001) was strongly associated with non-obese NAFLD after adjustment with various known risk factors.
Conclusions In addition to VFO, sarcopenia and/or myosteatosis were significantly associated with non-obese NAFLD.
Citations
Citations to this article as recorded by
Sarcopenia and MASLD: novel insights and the future Chang-Hai Liu, Qing-Min Zeng, Won Kim, Seung Up Kim, Zobair M. Younossi, Giovanni Targher, Christopher D. Byrne, Christos S. Mantzoros, Phunchai Charatcharoenwitthaya, Isabelle Anne Leclercq, Manuel Romero-Gómez, Hong Tang, Ming-Hua Zheng Nature Reviews Endocrinology.2026; 22(3): 139. CrossRef
Intrinsic capacity, genetic susceptibility, and the risks of metabolic dysfunction–associated steatotic liver disease and cirrhosis Zhuoshuai Liang, Hongrui Zhang, Huizhen Jin, Wenhui Gao, Ruofei Li, Xinmeng Hu, Yi Cheng, Lingfei Guo, Yawen Liu International Journal of Surgery.2026; 112(1): 780. CrossRef
Sarcopenia as a risk factor for nonalcoholic fatty liver disease and liver fibrosis: an updated systematic review and meta-analysis Xinrong Zuo, Doudou Chen, Yi Kang, Xinyi Hu, Yarong Zhang, Kuo Tang, Junhua Shi, Tao Li, Wangning Shangguan Frontiers in Nutrition.2026;[Epub] CrossRef
Type 2 diabetes mellitus Melanie J. Davies, Soo Lim, Tommy Slater, Jonathan Goldney, Athena Philis-Tsimikas, Denise R. Franco, Roberta Lamptey, Thomas Yates, Tsvetalina Tankova, Ildiko Lingvay Nature Reviews Disease Primers.2026;[Epub] CrossRef
Refining intergenerational MASLD risk: are measurement and mediation shaping the signal? Tien Manh Huynh, Thinh Ong, Naveen Gautam, Hung Song Nguyen Gut.2026; : gutjnl-2026-338664. CrossRef
CT-assessed abdominal visceral adiposity and MASLD: a sex-stratified cross-sectional analysis Linying Xu, Ting Chen, Yitian Xie, Xueyu Xiang, Yupeng Liu, Chongyong Xu, Shuran Wang Frontiers in Nutrition.2026;[Epub] CrossRef
The Relationship Between Remnant Cholesterol and Visceral Adipose
Tissue: A National Cross-Sectional Study Zhaoxiang Wang, Shao Zhong, Menghuan Wu, Xuejing Shao, Tian Gu, Mengjiao Xu, Qichao Yang Hormone and Metabolic Research.2025; 57(01): 47. CrossRef
Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases Qi Zhong, Rui Zhou, Yi-Ning Huang, Rui-Dian Huang, Fu-Rong Li, Hao-Wen Chen, Yan-Fei Wei, Kuan Liu, Bi-Fei Cao, Kai-Yue Liao, Zheng-Yun Xu, Shi-Ao Wang, Xian-Bo Wu Journal of Hepatology.2025; 82(3): 427. CrossRef
Statin use and liver-related prognosis among patients with MASLD Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon JHEP Reports.2025; 7(4): 101313. CrossRef
AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B Hyunjae Shin, Moon Haeng Hur, Byeong Geun Song, Soo Young Park, Gi-Ae Kim, Gwanghyeon Choi, Joon Yeul Nam, Minseok Albert Kim, Youngsu Park, Yunmi Ko, Jeayeon Park, Han Ah Lee, Sung Won Chung, Na Ryung Choi, Min Kyung Park, Yun Bin Lee, Dong Hyun Sinn, Se Journal of Hepatology.2025; 82(6): 1080. CrossRef
Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease Jessica M. Rubino, Natalie Yanzi Ring, Krishna Patel, Xiaoqing Xia, Todd A. MacKenzie, Roberta M. diFlorio-Alexander Biomedicines.2025; 13(1): 80. CrossRef
Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang European Journal of Gastroenterology & Hepatology.2025; 37(5): 652. CrossRef
A cross-sectional study of risk factors associated with sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease Johnny Amer, Qusay Abdoh, Zaina Salous, Eithar Abu Alsoud, Sama AbuBaker, Ahmad Salhab, Manal Badrasawi Frontiers in Medicine.2025;[Epub] CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S Hepatology International.2025; 19(2): 261. CrossRef
Sarcopenia and non-alcoholic fatty liver disease - complex pathogenetic relationships V. A. Akhmedov, V. S. Marinenko Experimental and Clinical Gastroenterology.2025; (9): 110. CrossRef
Effects of Pemafibrate on Serum Carnitine and Plasma Myostatin in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease Ryohei Tanigawa, Atsushi Nakajima, Yuichiro Eguchi, Hirokazu Takahashi, Rohit Loomba, Hideki Suganami, Masaya Tanahashi, Hidenori Arai JCSM Communications.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies Parag Jain, Akanksha Jain, Rohitas Deshmukh, Pradeep Samal, Trilochan Satapathy, Ajazuddin Clinics and Research in Hepatology and Gastroenterology.2025; 49(6): 102584. CrossRef
Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon Liver International.2025;[Epub] CrossRef
Skeletal muscle and MASLD: Mechanistic and clinical insights Thomas Marjot, Matthew J. Armstrong, Jonathan G. Stine Hepatology Communications.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass Vasily Isakov World Journal of Gastroenterology.2025;[Epub] CrossRef
Association of lean metabolic dysfunction‐associated steatotic liver disease with carotid plaque progression in patients with type 2 diabetes mellitus Youngjoon Kim, Yongin Cho, Yong‐ho Lee, Da Hea Seo, Seong Hee Ahn, Seongbin Hong, So Hun Kim Journal of Diabetes Investigation.2025; 16(9): 1713. CrossRef
Role of estimated glucose disposal rate in predicting myosteatosis: Insights from abdominal CT analysis Myung Jin Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Woo Je Lee, Hong-Kyu Kim, Chang Hee Jung Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(12): 104225. CrossRef
Thigh Muscles and Metabolic Dysfunction‐Associated Steatotic Liver Disease: Findings From the SCAPIS/IGT‐Microbiota Study Amar Osmancevic, Anders Gummesson, Matthew Allison, Joel Kullberg, Ying Li, Göran Bergström, Bledar Daka Liver International.2025;[Epub] CrossRef
Influence of Matcha and Tea Catechins on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)—A Review of Patient Trials and Animal Studies Danuta I. Kosik-Bogacka, Katarzyna Piotrowska Nutrients.2025; 17(15): 2532. CrossRef
Associations of child-to-adult body size change with risk of hypertension and metabolic dysfunction-associated steatotic liver disease: a population-based cohort study of 226,420 individuals Fengyuan Tang, Wenqianzi Yang, Weijia Wu, Shengxuan Jin, Xuemei Zhen, Hengjin Dong BMC Public Health.2025;[Epub] CrossRef
The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is associated with early onset type 2 diabetes with NAFLD: a cross-sectional study in China Nini Wu, Yingqun Ni, Rilong Huang, Junhua Wang, Meimei Li, Haiying Hu, Yuanyuan Zhang, Juyi Li, Jinjun Zhang Frontiers in Nutrition.2025;[Epub] CrossRef
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists Muhammad Shahzeb Khan, Syed Sarmad Javaid, Amreen Dinani, Kara Wegermann, Ambarish Pandey, Ankeet S. Bhatt, Mark Muthiah, Harriette G.C. Van Spall, Faiez Zannad, Javed Butler, Michael L. Volk, Marat Fudim JACC.2025; 86(20): 1861. CrossRef
Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis Aikaterini Kamiliou, Vasileios Lekakis, Lampros Chrysavgis, Evangelos Cholongitas Hepatology International.2024; 18(2): 688. CrossRef
Prevalence of and Impact on the Outcome of Myosteatosis in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Aikaterini Kamiliou, Vasileios Lekakis, George Xynos, Evangelos Cholongitas Cancers.2024; 16(5): 952. CrossRef
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting Alina M. Allen, Michael Charlton, Kenneth Cusi, Stephen A. Harrison, Kris V. Kowdley, Mazen Noureddin, Jay H. Shubrook Postgraduate Medicine.2024; 136(3): 229. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options Piero Portincasa, Mohamad Khalil, Laura Mahdi, Valeria Perniola, Valeria Idone, Annarita Graziani, Gyorgy Baffy, Agostino Di Ciaula International Journal of Molecular Sciences.2024; 25(11): 5640. CrossRef
Association between metabolic dysfunction‐associated steatotic liver disease and myosteatosis measured by computed tomography Myung Jin Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Woo Je Lee, Hong‐Kyu Kim, Chang Hee Jung Journal of Cachexia, Sarcopenia and Muscle.2024; 15(5): 1942. CrossRef
The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis Xiaoyan Li, Jie He, Qiuhua Sun Clinical Nutrition.2024; 43(9): 2005. CrossRef
Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 705. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung Cancers.2024; 16(18): 3161. CrossRef
Diagnosis and management of metabolic dysfunction- associated steatotic liver disease in South Asians- A clinical review Prajith Raj Ramesh, Priya Krishnan, Samyuktha Prabu, Varshini Srinivasan, Varalakshmi Niranjan Obesity Pillars.2024; 12: 100142. CrossRef
Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review Basile Njei, Prince Ameyaw, Yazan Al-Ajlouni, Lea-Pearl Njei, Sarpong Boateng Cureus.2024;[Epub] CrossRef
Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan Clinical and Molecular Hepatology.2024; 30(4): 1039. CrossRef
Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim Clinical and Molecular Hepatology.2024; 30(4): 989. CrossRef
Correlation and predictive value of novel anthropometric indicators with adult sarcopenia and sarcopenia obesity Xue Wu, Ziang Chen, Yuanhui Zhao, Hong Ren Scientific Reports.2024;[Epub] CrossRef
Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It? Catherine Stankevicius, Rachel H. Davis, Dep Huynh, Martine Hatzi, Stephanie Morgillo, Alice S. Day Journal of Digestive Diseases.2024; 25(11-12): 645. CrossRef
Non-alcoholic fatty liver disease in people with normal body weight S. V. Turkina, I. A. Tyshchenko, M. N. Titarenko Experimental and Clinical Gastroenterology.2024; (10): 36. CrossRef
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean? Eugene Han, Yong-ho Lee Clinical and Molecular Hepatology.2023; 29(4): 980. CrossRef
Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved Baris Afsar, Rengin Elsurer Afsar Clinical Nutrition.2023; 42(12): 2338. CrossRef
The newly proposed Metabolic Score for Visceral Fat is a reliable tool for identifying non-alcoholic fatty liver disease, requiring attention to age-specific effects in both sexes Maobin Kuang, Jiajun Qiu, Dongdong Li, Chong Hu, Shuhua Zhang, Guotai Sheng, Yang Zou Frontiers in Endocrinology.2023;[Epub] CrossRef
First
Prev
